Blog

LAFAYETTE, LA / ACCESS Newswire / September 23, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it has completed all repurchases authorized under its previously announced share repurchase program.

On June 9, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to 1,976,441 common shares, representing approximately 5% of the total issued and outstanding shares at the time of authorization.

The Company has completed the repurchase and cancellation of all 1,976,441 common shares authorized under the program, for a total cost of approximately $13.2 million at a weighted average price of $6.69 per share, before taxes. The repurchases were executed through open market transactions in accordance with applicable securities laws.

Casey Hoyt, Viemed’s Chief Executive Officer, commented, “Completing this share repurchase program highlights both our confidence in Viemed’s long-term outlook and our ongoing commitment to enhancing shareholder value. With our strong balance sheet and ample liquidity driven by increasing free cash flow, we remain well positioned to continue investing in growth opportunities while returning capital to shareholders.”

ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s ability to continue to execute its capital allocation strategies, fund organic and inorganic growth initiatives, and create shareholder value, are forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further information, please contact:

Investor Relations

ir@viemed.com
Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
337-504-3802

SOURCE: Viemed Healthcare, Inc.

View the original press release on ACCESS Newswire

Expanded, multi-function engagement validates September 4 growth plan and strengthens recurring revenue trajectory

NEW YORK CITY, NEW YORK / ACCESS Newswire / September 24, 2025 / New to The Street, one of the fastest-growing financial media platforms with over 3.5 million YouTube subscribers and weekly national broadcasts on Fox Business and Bloomberg, highlights the recent announcement from its esteemed client, Aeries Technology, Inc. (NASDAQ:AERT).

Aeries Technology, a global leader in AI-powered business transformation and Global Capability Center (GCC) services, announced the expansion of an engagement with a recently signed global enterprise client. The broadened scope is expected to drive the client relationship to an annualized revenue run-rate exceeding $12 million by fiscal year-end (March 2026), with additional growth anticipated in subsequent quarters.

The client is expanding its use of Aeries’ platform across artificial intelligence, technology services, finance, and customer support, leveraging Aeries’ established delivery hubs in India and Mexico.

Ajay Khare, CEO of Aeries Technology, stated:
“This expansion demonstrates the scalability of our model and reflects the trust global enterprises have in us. We are successfully converting initial engagements into recurring revenue streams. Importantly, this deal reinforces confidence in our multi-year growth trajectory.”

Vince Caruso, Co-Founder and CEO of New to The Street, added:
“Aeries Technology is a prime example of the innovative, fast-growing companies we proudly feature. Their ability to scale quickly while securing major enterprise expansions showcases the type of forward-looking success stories our platform was built to spotlight. We congratulate Ajay and his team on this significant milestone.”

This expansion builds on Aeries’ previously announced plans to add 500 full-time employees across India and Mexico, strengthening its ability to meet surging client demand.

About Aeries Technology

Aeries Technology (NASDAQ: AERT) is a global leader in AI-enabled value creation, business transformation, and Global Capability Center (GCC) delivery for private equity (PE) portfolio companies, supporting scalable, technology-driven execution. Founded in 2012, its commitment to workforce development has earned it Great Place to Work Certification for two consecutive years.

About New to The Street

Since 2009, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television brands, broadcasting weekly on Fox Business and Bloomberg as sponsored programming. With over 3.5 million YouTube subscribers, iconic Times Square billboards, and guaranteed earned media placements, New to The Street delivers its trademark “Opportunities To Consider™” segments, helping public and private companies tell their stories to investors, business leaders, and audiences worldwide.

Media Contacts:

• Aeries Technology: IR@aeriestechnology.com

• New to The Street: Monica Brennan, Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 23, 2025 / Decades of global conferences have carried genuine ambition to solve the twin crises of recycling and safety. Year after year, leaders from around the world gather with the intent to act, pledging bold commitments and setting inspiring targets. The passion is real, the urgency is evident, and the desire to create meaningful change is undeniable.

But intent on its own is not enough. Promises without tools for enforcement eventually falter, and progress stalls. That was the hard truth COP 29 made impossible to ignore. Despite the strength of the pledges, none of them came with systems to measure, verify, or ensure follow-through. Without enforcement, even the best-intentioned commitments risk becoming theater. And the cost of that gap is tangible: recycling systems that fall short, safety standards that fail when tested, and tragedies that remind us paper declarations cannot protect people.

This is where local proof becomes essential. If global diplomacy cannot enforce its own rules, technology can. The company providing that proof is SMX (NASDAQ:SMX), which embeds solutions at the molecular level to turn sustainability from promise into measurable performance.

The Missing Piece of Enforcement

At the heart of every failed pledge is the same weakness: unenforceable standards. A target is set, but no system exists to verify it. A regulation is written, but no technology can measure it in real time. For decades, governments and industries have been forced to rely on self-reporting – the same green logos on packaging, the same safety datasheets, the same claims that collapse when examined.

SMX replaces those claims with embedded molecular proof. A scan of a product now verifies whether it truly contains recycled content, whether flame retardants are present and effective, and whether those pesky black carbon plastics, once almost exclusively destined for landfills, are accounted for. Enforcement is no longer an act of faith. It is automatic, built into the material itself.

That shift is profound. It transforms regulation from aspiration into application, from targets on paper into standards enforced in practice.

Local Enforcement in Action

The clearest proof comes from Singapore. By working with A*STAR, SMX is laying the foundation for a national plastics passport. Every piece of plastic carries its own verified identity. Regulators don’t have to trust corporate reports; they can enforce policy molecule by molecule. That’s not diplomacy. That’s execution.

In Europe, SMX’s planned partnership with REDWAVE will embed verification directly into industrial processes. Compliance stops being a quarterly exercise and becomes a continuous process. Every item on a conveyor belt can be scanned and certified. Even the plastics that once escaped every detection system can now be verified. That’s local enforcement working in real time.

In North America, the opportunity with the North American Flame Retardant Alliance (NAFRA) extends this model into safety. For the first time, regulators can confirm compliance in products themselves, not just on paper. This is enforcement that doesn’t wait for tragedy to expose weakness. It prevents it.

From Talk to Trust

The difference is clear. Global pledges have shown us what talk looks like. Local enforcement shows us what trust feels like. The former fills headlines. The latter fills markets, policies, and homes with certainty.

For governments, this is the missing link – the ability to enforce policy not with endless penalties, but with verifiable proof. For manufacturers, it’s clarity: compliance isn’t subjective, it’s a scan away. For insurers, it’s measurable risk. And for consumers, it’s finally an end to the doubt that recycling claims or safety standards are just words.

SMX is proving that the path forward doesn’t run through another round of conferences. It runs through real enforcement, embedded locally, in real time, inside the materials themselves. Global pledges are falling short. Local proof is winning. And it’s rewriting the future of sustainability and safety, not in declarations, but in molecules.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 23, 2025 / New to The Street, one of the fastest-growing financial media brands with over 3.5 million YouTube subscribers and weekly national broadcasts on Fox Business and Bloomberg, announced today it is in discussions with Brag House, a Gen Z engagement platform operating at the intersection of gaming, college sports, and digital media, to explore a potential strategic collaboration.

As part of this developing relationship, Brag House will film its first segments at the New York Stock Exchange later this week, which will broadcast on Bloomberg on Saturday, October 4, at 6:30 PM EST. The program will be supported by iconic billboards, earned media placements, national TV commercials, and ongoing daily social media engagement.

Lavell Juan, CEO of Brag House, commented:
“Brag House is redefining how brands and colleges connect with Gen Z through gaming, college sports, and data-driven engagement. Exploring a collaboration with New to The Street gives us a powerful platform to share that story with investors and business leaders nationwide, ensuring our vision is seen with the reach and credibility it deserves.”

Vince Caruso, Co-Founder and CEO of New to The Street, added:
“We are always looking for next-generation platforms that resonate with younger audiences while providing measurable impact. Brag House has built an exciting community model around Gen Z engagement, and we look forward to seeing where these discussions may lead.”

About Brag House

Brag House is a Gen Z-focused media-tech platform that blends college sports, gaming, and community-driven engagement. By combining interactive content with data analytics, Brag House empowers brands and universities to authentically connect with the next generation at scale.

About New to The Street

Since 2009, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television brands, broadcasting weekly on Fox Business and Bloomberg as sponsored programming. With over 3.5 million YouTube subscribers, iconic Times Square billboards, and guaranteed earned media placements, New to The Street delivers its trademark “Opportunities To Consider™” segments, helping public and private companies tell their stories to investors, business leaders, and audiences worldwide.

Media Contact:
Monica Brennan
New to The Street
Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal year ended June 30, 2025.

Revenue for the quarter ended June 30, 2025 was $14.2 million compared to $12.7 million for the quarter ended June 30, 2024, an increase of $1.5 million or 11.8%. The Company had operating income of approximately $589,000 and $402,000 in the quarters ended June 30, 2025 and 2024, respectively.

Revenues for the fiscal year ended June 30, 2025 were $54.3 million compared to $50.3 million for the fiscal year ended June 30, 2024, an increase of $4.0 million or 8.0%. The Company had operating income for the fiscal year ended June 30, 2025 of approximately $0.6 million compared to operating income of $0.3 million for the fiscal year ended June 30, 2024.

For the quarter ended June 30, 2025, the Company had a net loss of approximately $0.2 million or $0.01 per share of common stock, compared with net income of $0.3 million or $0.01 per share of common stock for the quarter ended June 30, 2024. The Company’s diluted net (loss) income per share of common stock for the quarters ended June 30, 2025 and 2024 were $(0.01) and $0.01 per share of common stock, respectively.

For the fiscal year ended June 30, 2025, the Company had net income of approximately $808,000 or $0.03 per share of common stock, compared with a net income of $112,000 or $0.00 per share of common stock for the fiscal year ended June 30, 2024. The Company’s diluted net income per share of common stock for the fiscal years ended June 30, 2025 and 2024 were $0.03 and $0.00 per share of common stock, respectively.

“Our revenues increased by 8.0% in the fiscal year ended June 30, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 84% and 90% of total revenue in the fiscal year ended June 30, 2025 and 2024, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. “We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue,” the Co-CEOs further stated.

A summary of our financial results for the three months and fiscal years ended June 30, 2025 and 2024 follows:

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962

SOURCE: Integrated BioPharma, Inc.

View the original press release on ACCESS Newswire

9/24/2025: Headline verbiage changed

INDIANAPOLIS, INDIANA / ACCESS Newswire / September 24, 2025 / Arrive AI (NASDAQ:ARAI), a pioneer in autonomous last-mile delivery, is experiencing rapid hiring and expansion at the same time TechPoint, Indiana’s tech growth initiative, is urging the state to seize opportunities in artificial intelligence (AI).

In its new AI Driven Skills for Indiana’s Economy report, TechPoint highlights a surge in demand for AI jobs and warns that Indiana risks losing ground if it does not accelerate workforce training and adoption. Magnit workforce data published in July 2025 validates TechPoint’s concern, showing that AI and automation roles filled doubled year-over-year in the first quarter of 2025, growing from 3 percent to 6 percent of all roles filled, even as overall Information Technology hiring contracted. That report said AI “is emerging as a critical area for workforce growth, reshaping job functions and creating new roles across industries.”

Arrive AI is setting the standard as it applies to AI hiring in Indiana. The company is on track to grow from six full-time employees in January 2025 to 60 by year-end, with a strong focus on AI scientists, software engineers, and product developers. The company’s total workforce stands at 31 today.

“I was astounded and excited to see the access to high tech talent that was readily available to us right here in the Midwest,” said Dan O’Toole, Arrive AI founder and CEO. “It’s the tech of the future, and we see lots of evidence that Indiana can lead the way in AI talent development.”

“TechPoint’s report makes it clear that Indiana must move quickly to build AI-driven innovation and job creation,” said Sally Reasoner, vice president, talent strategy, TechPoint. “Arrive AI is showing us that the talent is already here and ready. It’s now on all of us as employers to open doors, create opportunities, and build the future together.”

Arrive AI’s patented Autonomous Last Mile platform enables secure, efficient delivery to and from smart, AI-powered Arrive Points™, whether by drone, ground robot, or human courier. The system integrates AI-driven logistics with real-time tracking, advanced chain-of-custody controls, and compatibility with smart home devices.

The company’s hiring surge reflects Indiana’s growing pool of tech talent. While Arrive AI advertised nationally, more than half of its recent hires are based in central Indiana. New employees bring experience from Apple, Meta, Pinterest, NASA projects, and numerous startups.

Tom Hunley, Arrive AI’s human resources generalist, is leading recruitment after previous roles at Roche Diagnostics, Jobvite, and other tech firms.

“I’m really impressed with the caliber of the applicant pool,” Hunley said. “We’ve seen more than 1,300 resumes in just weeks, and many candidates already have deep experience in AI, technology, and manufacturing.”

Arrive AI also is building strong university partnerships with Indiana University, Trine University, Purdue University, Rose-Hulman Institute of Technology, and the University of Cincinnati to attract and train the next generation of AI talent.

“Everyone is hitting the ground running,” said Mark Hamm, Arrive AI’s chief operating officer. “That’s critical for any company, but especially one like ours that’s building technology of the future.”

The company’s momentum follows its May 2025 Nasdaq debut and $40 million commitment, which is fueling the company’s aggressive growth in hiring and technology development.

TechPoint’s report calls on Indiana to:

• Create cross-sector AI knowledge exchanges to accelerate best practices.

“Arrive AI is proof of Indiana’s potential to lead in AI innovation and job creation,” O’Toole added. “We are building that future here and now.”

-30-

About Arrive AI: Arrive AI (NASDAQ:ARAI) is a Fishers, Indiana-based technology company revolutionizing autonomous last-mile delivery. Its patented Autonomous Last Mile™ platform integrates AI, robotics, and logistics to provide secure, efficient deliveries through its network of AI-powered Arrive Points™. The company partners with delivery providers, retailers, and smart home platforms to streamline the delivery experience and expand AI-driven job opportunities in Indiana and beyond.

Learn more at https://www.arriveai.com and via the company press kit.

Media contact: Cheryl Reed at media@arriveai.com

Investor Relations Contact: Alliance Advisors IR at ARAI.IR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “on track of”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, success in securing desired workforce, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement and other filings with the Securities and Exchange Commission, for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

National competition gives students the opportunity to work with one of North America’s leading newswire services

RALEIGH, NC / ACCESS Newswire / September 23, 2025 / ACCESS Newswire Inc. (NYSE American:ACCS), one of the top three newswire and PR platforms in North America, has been selected as the client partner for the 2026 Public Relations Student Society of America (PRSSA) Bateman Case Study Competition, the organization’s premier national student competition.

The Bateman Competition challenges undergraduate public relations students across the country to create comprehensive campaigns for a real-world client. This year, participating teams will develop strategic and creative solutions designed to build awareness and engagement for ACCESS Newswire, with a focus on showcasing how the company continues to support and elevate the communications industry.

“We are honored to partner with PRSSA and the Bateman Competition,” said Jennifer Hammers, EVP Sales & Marketing at ACCESS Newswire. “For nearly two decades, we’ve been helping organizations share their stories and strengthen their brands. Partnering with the next generation of communicators is a natural extension of that mission.”

Finalist teams will be selected in Spring 2026 to present their campaigns to a panel of judges, with winners announced in May. The top three teams will receive national recognition and monetary awards.

“As one of the most rewarding and challenging programs PRSSA offers, Bateman allows students to gain hands-on experience with a real client while sharpening their research, strategy, and execution skills,” said Jeneen Garcia, Chief Programs Officer at PRSA.

Additional Competition information will be posted on the PRSSA website by Sept. 25.

About ACCESS Newswire
We are ACCESS Newswire, a global trusted Public Relations (PR) and Investor Relations (IP) solution provider. With a focus on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands to connect with their audience where it matters most. From start-ups to multi-billion-dollar global brands, we ensure your most important moments make an impact and resonate with your audiences. To learn more visit www.accessnewswire.com.

For further information:
ACCESS Newswire
Jennifer Hammers
888.808.2227 | jenniferh@accessnewswire.com

SOURCE: ACCESS Newswire Inc.

View the original press release on ACCESS Newswire

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer

D-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity

PHILADELPHIA, PA / ACCESS Newswire / September 24, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that members of its executive management team will participate in a live fireside chat on Monday, September 29, 2025, hosted by Kumaraguru (Kumar) Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets.

Following a company overview from Dr. Raza Bokhari Executive Chairman and CEO of Medicus Pharma, there will be two featured presentations providing updates on the Company’s key development programs:

• Ed Brennan, MD, FACS Chief Scientific Officer & Head of R&D Program, will discuss SkinJect™ D-MNA novel treatment to non-invasively treat basal cell carcinoma (BCC) of the skin and provide an update on the progress of phase 2 clinical studies.

• Faisal Mehmud, MD, MRCP, Chief Medical Officer, will provide an update on Teverelix, a next generation GnRH antagonist as a first in class market product to prevent relapse of acute urinary retention (AURr) and high CV risk prostate cancer.

The fireside chat will conclude with a Q&A session during which participants can ask questions live or submit them during the webcast. Please note this event will be live only; there will be no publicly available recording or archived webcast.

The Company’s lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially BCC, using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells.

The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:
Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. . Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

Strengthening Domestic Critical Mineral Supply

SAN BERNARDINO, CALIFORNIA / ACCESS Newswire / September 24, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) is pleased to announce that second ModEM 3D magneto-telluric (MT) inversion result has also confirmed the high-priority REE drill target on line 2200N at its 100%-owned Colosseum Gold-REE Project, California. This target was originally identified in August using Viridien’s RLM-3D inversion model. The latest modelling, an independent inversion by Dr. Kate Selway of Vox Geophysics using the open-source ModEM code, produced a very similar 3D resistivity model, validating the earlier interpretation.

Highlights

• ModEM Model Review: A second 3D MT inversion model has confirmed the high priority 2200N REE target, located just north of the historical gold open pits.

• Model Consistency: The RLM-3D and new ModEM inversions produced resistivity models with very similar features, providing strong cross-validation of the target.

• Deep, Coincident Anomaly: In both models, a resistive region extends to at least ~1,000 m depth below the surface, spatially coincident with outcropping REE bearing fenite dykes (consistent with an REE bearing carbonatite source).

• Upcoming Drilling:Majors Drilling will mobilise additional rigs in coming weeks to expedite testing of this high-priority REE drill target.

• Parallel Validation Underway for Gold Targets: A second-party review is in progress to validate the six new gold breccia pipe targets identified in August 2025, strengthening confidence ahead of drill testing.

In both models, a prominent resistive anomaly is observed on line 2200N, extending from ~1,000 m depth up to surface and coincident with surface fenite dykes. Notably, this resistive body’s alignment with fenite (an alteration typically haloing carbonatite intrusions) is consistent with a carbonatite source, indicating carbonatite-hosted potential for REE mineralisation at depth

Dateline’s Managing Director, Stephen Baghdadi, commented:

“This new modelling, conducted by two highly skilled groups, using different analysis software and inversion modelling methods have both confirmed the exciting 2200N rare earth target, we look forward to drill testing our new REE and gold targets and adding further value for shareholders.”

Figure 1: 3D MT resistivity cross-section (Line 2200N) modelled using Viridien’s RLM-3D inversion. The prominent high-resistivity anomaly (blue zones) extends from ~1,000 m depth to surface beneath the area of known fenite dykes. This deep resistive body is interpreted as a potential carbonatite intrusion associated with REE mineralisation. (Vertical axis in metres; horizontal axis in metres along line.)

Figure 2: 3D MT resistivity cross-section (Line 2200N) from the independent ModEM inversion by Vox Geophysics. The ModEM result reveals an almost identical resistive anomaly (Blue) in the same location and depth range as the RLM-3D model. This independent replication strongly validates the target’s robustness. The consistency between the two models underscores this high-priority anomaly’s carbonatite-hosted potential as an REE system.

Magneto-Telluric Inversion Modelling

The MT survey data (167 stations on 14 lines) were reprocessed by Vox Geophysics using the ModEM inversion algorithm to generate a fresh 3D resistivity model for the Colosseum Project.

Figure 3: Plan view of Colosseum claim boundary showing MT survey lines and REE bearing fenite outcrops in black diamonds.

Dr. Selway, a globally recognized expert in magneto-telluric data analysis with over 20 years of experience, holds a PhD in MT methodologies and has conducted fieldwork across diverse regions, including Antarctica, Greenland, East Africa, Australia, and the United States. Her extensive academic background includes roles at prestigious institutions such as the University of Adelaide, Yale University, Lamont-Doherty Earth Observatory, and the University of Oslo, complemented by contributions to high-profile geophysical publications.

Dr Kate Selway, Managing Director of Vox Geophysics, noted: “The two independent RLM-3D and ModEM approaches, with independent data analysis and different inversion codes, have produced resistivity models with very similar features. This cross-validation between the two independent approaches provides confidence that features consistently imaged in both models are robust and reliable.”

This independent model closely mirrors the original RLM-3D model, confirming all major resistive and conductive features. Crucially, the east-west Line 2200N anomaly – previously highlighted as a zone of REE potential – appears virtually identical in both models. In each case, a broad high-resistivity zone (hundreds of metres across) rises from at least ~1 km depth to the near-surface, directly beneath outcrops of fenite dykes. The duplication of this feature by two independent inversion codes greatly reinforces confidence in its geologic significance. The spatial coincidence of a deep-seated resistive body with surface fenite alteration is a signature characteristic of carbonatite-centred REE systems, suggesting that the 2200N anomaly may represent a carbonatite intrusive source for REE mineralisation. This interpretation aligns with other geophysical evidence at Colosseum, where the 2200N target area also shows a gravity high and magnetic low pattern analogous to the nearby Mountain Pass carbonatite REE deposit (~10 km south).

Next Steps: Drilling and Exploration Strategy

Drill Testing: Dateline plans to commence drill testing of the new rare earth target on line 2200N (along with several new gold targets) in the upcoming December quarter. Diamond drilling is already underway at Colosseum, focused on infill and extensional holes in the existing gold mineral resource as part of a Bankable Feasibility Study (BFS). Drill rigs are being mobilised to site through September-October to accelerate the exploration program and fast-track the testing of newly defined targets. The 2200N anomaly, now supported by two independent 3D models and surface geological indicators, is regarded as a high-priority REE drill target and will be a key focus of the upcoming campaign.

Importantly, the area of the 2200N anomaly has seen no historical drilling. Past exploration at Colosseum was largely gold-focused and concentrated around the known breccia pipe gold outcrops, leaving the REE potential of the broader system underexplored. The newly defined 2200N target therefore represents a potential fresh discovery.

Broader Exploration Strategy: The validation of this REE target is in keeping with Dateline’s dual-track strategy at Colosseum of advancing the known gold deposit toward development while unlocking new value in the project’s rare earth and additional potential gold bearing breccia pipe targets. The Company’s rigorous approach to data collection, now bolstered by the latest 3D MT results, is designed to de-risk drill targeting and maximize the chance of discovery. Dateline’s technical team will incorporate the ModEM model insights into final drill planning for the REE targets.

MT Gold Target Review: In addition to the REE inversion validation, Dateline has initiated a secondary review of the gold-focused MT model. This review aims to independently validate the six high-priority breccia pipe targets announced in August 2025. Results from this validation will be disclosed to the market when completed and integrated into the final drill targeting model as Dateline prepares to test both gold and REE targets in the current campaign.

This press release has been authorized for release by the Board of Dateline Resources Limited.

For more information, please contact:

Stephen Baghdadi
Managing Director
+61 2 9375 2353

Andrew Rowell
Corporate & Investor Relations Manager
+61 400 466 226
a.rowell@dtraux.com
www.datelineresources.com.au

Follow Dateline on socials:
X – @Dateline_DTR
Truth Social – @dateline_resources
LinkedIn – dateline-resources

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1.F) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.

The Colosseum is located less than 10km north of the Mountain Pass Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Dateline has also acquired the high-grade Argos Strontium Project, also located in San Bernadino County, California. Argos is reportedly the largest strontium deposit in the U.S. with previous celestite production grading 95%+ SrSO4.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Competent Person Statement

Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.

Company Confirmations

The Company confirms it is not aware of any new information or data that materially affects the information included in the announcements dated 23 October 2024 with regard to the Colosseum MRE and 23 May 2025 with regard to Colosseum Project Economics. Similarly, the Company confirms that all material assumptions and technical parameters underpinning the estimates and the forecast financial information referred to in those previous announcements continue to apply and have not materially changed.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

• Players are invited to “Shrink and Explore the Real World” in a new cosy game, where you become a tiny adventurer

• Animula Nook is available now for wishlist on Steam, Epic Games Store, and PlayStation, and will be coming to Switch 2 and Mac

• Sign up to Discord to become part of the Alpha testing team

GUANGZHOU, CN / ACCESS Newswire / September 23, 2025 / LilliLandia Games, an indie studio under Tencent Games specialising in the life simulation genre and integrating both development and publishing, is proud to announce its upcoming title, Animula Nook, a fantasy life simulation game set in a lilliputian world. Blending whimsical characters with richly interactive environments, the game aims to offer players an enchanting, creative and cozy experience.

Watch the official trailer for Animula Nook here.

Inspired by the charm of modern animated cartoons, Animula Nook transforms everyday objects into fantastical landscapes. From towering coffee mugs to sprawling bookshelves, players become tiny explorers in a giant’s world. They can navigate and interact with oversized, real-world objects, build their own homestead, collect elements such as raindrops and wind to help with crafting, and grow crops in flowerpots.

Animula Nook offers players a haven where they can explore, create and forge friendships. The game also supports online functionality, allowing players to share their creativity and experiences with their family and friends.

Key Features of Animula Nook:

• Discover a tiny yet immense world: Venture into vibrant landscapes hidden in plain sight. Explore lush, resource-packed houseplant forests, delve into the mysterious depths of a forgotten well, and navigate other awe-inspiring (and sometimes perilous) corners of your home. Every expedition is an adventure, whether you are unearthing rare materials or meeting a new friend.

• Collect beyond the ordinary: In this tiny world, sunlight, raindrops, gentle breezes-even forgotten scents-become precious materials waiting to be discovered. Coins, buttons, and other small wonders are scattered throughout the land – each one not just a resource, but a lost treasure waiting for a new purpose.

• Build with everyday objects: Milk cartons become charming houses, teacups turn into bustling cafés, and spice jars transform into tiny, glowing shops. Use the objects around you to build, decorate, and customize a miniature haven with unique furniture and personal touches. Start on your desk, then expand your creations across windowsills, cabinets, or even inside a vibrant, living vivarium.

• Befriend the world’s tiny folk: This miniature world is full of life. Meet a delightful cast of residents, from tiny humanoids to whimsical beings you’ve never seen before. Exchange gifts, create memories, and watch as your bonds deepen over time. As you grow closer, their stories will unfold in more personal and surprising ways. With enough care, you might even convince them to move in – just be sure to build them a space they’ll love.

• Define yourself in every detail: Customize your character, express yourself creatively, and make the world truly yours. With an endless assortment of outfits, accessories, furniture, and tools, everything you create is a reflection of you.

• Convenient creative tools: Bring your ideas to life with intuitive tools that make creativity effortless. Sketch blueprints for builds, dismantle objects into modular components, and see your imagination come to life with ease.

Animula Nook will make its first appearance at Tokyo Game Show this week, September 25th to 28th. Attendees can visit the booth in Hall 6 06S02 to get a first look at gameplay and secure exclusive gifts.

Animula Nook is available for wishlist on Steam, Epic Games Store, and PlayStation, and will be available for Switch 2 and Mac. Players who wishlist the title will receive updates on upcoming announcements, release timelines, and exclusive content reveals.

Join the official Discord server, to become part of the Alpha testing team. Get early access to community events and rewards and hear from the development team.

For more information about Animula Nook, check out the website or follow the game on social channels: Facebook, X, Instagram, TikTok or YouTube.

About LilliLandia Games

LilliLandia Games is an experienced studio with mature cross-platform global development capabilities, built by a core team of veterans who specialise in platform development and multiplayer experiences. The team focuses on making games that provide social connection and comfort, creating beautiful worlds as a sanctuary for the global gaming community.

SOURCE: Tencent

View the original press release on ACCESS Newswire